Tempus reported an 85% year‑over‑year revenue jump in Q3 as the company positions its MRD (minimal residual disease) tests for reimbursement and seeks FDA submissions for multiple assays. Management told investors that Medicare coverage via MolDx is expected soon for a tumor‑naïve colorectal MRD test and that broader FDA filings are planned through 2026. The company is pursuing a mixed reimbursement and regulatory pathway — tumor‑informed and tumor‑naïve MRD approaches — to secure payor coverage and national coverage decisions. If successful, Tempus’s strategy could accelerate clinical adoption of liquid biopsy MRD testing and reshape payor dynamics for cancer monitoring diagnostics.